Citations (31)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Zhuangwei Lv, Ping Zhang, Dandan Li, Mengting Qin, Longzhu Nie, Xiaoqian Wang, Li Ai, Zhaozu Feng, Woodvine Otieno Odhiambo, Yunfeng Ma & Yanhong Ji. (2020) CD19-targeting fusion protein combined with PD1 antibody enhances anti-tumor immunity in mouse models. OncoImmunology 9:1.
Read now
Read now
Kui Li & Hongqi Tian. (2019) Development of small-molecule immune checkpoint inhibitors of PD-1/PD-L1 as a new
therapeutic strategy for tumour immunotherapy. Journal of Drug Targeting 27:3, pages 244-256.
Read now
Read now
Articles from other publishers (29)
Samia S. Messeha, Najla O. Zarmouh & Karam F. A. Soliman. (2021) Polyphenols Modulating Effects of PD-L1/PD-1 Checkpoint and EMT-Mediated PD-L1 Overexpression in Breast Cancer. Nutrients 13:5, pages 1718.
Crossref
Crossref
Chiara Agnoletto, Chiara Caruso & Cecilia Garofalo. (2021) Heterogeneous Circulating Tumor Cells in Sarcoma: Implication for Clinical Practice. Cancers 13:9, pages 2189.
Crossref
Crossref
Chih-Hung Guo, Simon Hsia, Chieh-Han Chung, Yi-Chun Lin, Min-Yi Shih, Pei-Chung Chen, Chia-Lin Peng, Susanne M. Henning, Guoo-Shyng W. Hsu & Zhaoping Li. (2021) Nutritional supplements in combination with chemotherapy or targeted therapy reduces tumor progression in mice bearing triple-negative breast cancer. The Journal of Nutritional Biochemistry 87, pages 108504.
Crossref
Crossref
敏博 延. (2019) Expressions and Clinical Significance of PD-L1 and PD-1 in Prostate Cancer. Asian Case Reports in Surgery 08:02, pages 9-14.
Crossref
Crossref
Yanchun Li, Mateusz Opyrchal, Song Yao, Xuan Peng, Li Yan, Hossam Jabbour & Thaer Khoury. (2018) The role of programmed death ligand-1 and tumor-infiltrating lymphocytes in breast cancer overexpressing HER2 gene. Breast Cancer Research and Treatment 170:2, pages 293-302.
Crossref
Crossref
Fei Li, Yi Ren & Zhandong Wang. (2018) Programmed death 1 Ligand 1 expression in breast cancer and its association with patients' clinical parameters. Journal of Cancer Research and Therapeutics 14:1, pages 150-154.
Crossref
Crossref
Angélica Aponte-López, Ezequiel M. Fuentes-Pananá, Daniel Cortes-Muñoz & Samira Muñoz-Cruz. (2018) Mast Cell, the Neglected Member of the Tumor Microenvironment: Role in Breast Cancer. Journal of Immunology Research 2018, pages 1-11.
Crossref
Crossref
Li-Wei Liu, Ming-Ya Yang, Min Zhou, Jia-Jia Li, Bo Liu & Yue-Yin Pan. (2017) Improvement of cytotoxicity of autologous CIKs from patients with breast cancer to MCF-7 cells by suppressed PD-1 expression. Cancer Biomarkers 20:4, pages 609-615.
Crossref
Crossref
Jian Lou, Yuefen Zhou, Jianhui Huang & Xiaojun Qian. (2017) Relationship between PD-L1 expression and clinical characteristics in patients with breast invasive ductal carcinoma. Open Medicine 12:1, pages 288-292.
Crossref
Crossref
Elena Brin, Katherine Wu, Hsin-Tze Lu, Yudou He, Zhaoming Dai & Wei He. (2017) PEGylated arginine deiminase can modulate tumor immune microenvironment by affecting immune checkpoint expression, decreasing regulatory T cell accumulation and inducing tumor T cell infiltration. Oncotarget 8:35, pages 58948-58963.
Crossref
Crossref
Jing Zhao, Peng Zhang, Jianhua Wang, Qingsong Xi, Xueqi Zhao, Minghua Ji & Guangyuan Hu. (2017) Plasma levels of soluble programmed death ligand-1 may be associated with overall survival in nonsmall cell lung cancer patients receiving thoracic radiotherapy. Medicine 96:7, pages e6102.
Crossref
Crossref
Yun-Feng Ma, Chen Chen, Dongqing Li, Min Liu, Zhuang-Wei Lv, Yanhong Ji & Jiru Xu. (2016) Targeting of interleukin (IL)-17A inhibits PDL1 expression in tumor cells and induces anticancer immunity in an estrogen receptor-negative murine model of breast cancer. Oncotarget 8:5, pages 7614-7624.
Crossref
Crossref
Luka Brčić, Luka Opašić & Helmut Popper. 2017. Mechanisms of Molecular Carcinogenesis – Volume 1. Mechanisms of Molecular Carcinogenesis – Volume 1
271
285
.
Arun Satelli, Izhar Singh Batth, Zachary Brownlee, Christina Rojas, Qing H. Meng, Scott Kopetz & Shulin Li. (2016) Potential role of nuclear PD-L1 expression in cell-surface vimentin positive circulating tumor cells as a prognostic marker in cancer patients. Scientific Reports 6:1.
Crossref
Crossref
Min Luo & Liwu Fu. (2016) The effect of chemotherapy on programmed cell death 1/programmed cell death 1 ligand axis: some chemotherapeutical drugs may finally work through immune response. Oncotarget 7:20, pages 29794-29803.
Crossref
Crossref
Emma M. Conway, Larissa A. Pikor, Sonia H. Y. Kung, Melisa J. Hamilton, Stephen Lam, Wan L. Lam & Kevin L. Bennewith. (2016) Macrophages, Inflammation, and Lung Cancer. American Journal of Respiratory and Critical Care Medicine 193:2, pages 116-130.
Crossref
Crossref
Mira A Patel. (2015) Present and future of immune checkpoint blockade: Monotherapy to adjuvant approaches. World Journal of Immunology 5:1, pages 1.
Crossref
Crossref
S. Muenst, A. R. Schaerli, F. Gao, S. Däster, E. Trella, R. A. Droeser, M. G. Muraro, P. Zajac, R. Zanetti, W. E. Gillanders, W. P. Weber & S. D. Soysal. (2014) Expression of programmed death ligand 1 (PD-L1) is associated with poor prognosis in human breast cancer. Breast Cancer Research and Treatment 146:1, pages 15-24.
Crossref
Crossref
Kurt A. Schalper, Vamsidhar Velcheti, Daniel Carvajal, Hallie Wimberly, Jason Brown, Lajos Pusztai & David L. Rimm. (2014)
In Situ
Tumor PD-L1 mRNA Expression Is Associated with Increased TILs and Better Outcome in Breast Carcinomas
. Clinical Cancer Research 20:10, pages 2773-2782.
Crossref
Crossref
Shenyou Sun, Xiaochun Fei, Yan Mao, Xiumin Wang, David H. Garfield, Ou Huang, Jinglong Wang, Fei Yuan, Long Sun, Qixiang Yu, Xiaolong Jin, Jianhua Wang & Kunwei Shen. (2014) PD-1+ immune cell infiltration inversely correlates with survival of operable breast cancer patients. Cancer Immunology, Immunotherapy 63:4, pages 395-406.
Crossref
Crossref
Sehar Afreen & Said Dermime. (2014) The immunoinhibitory B7-H1 molecule as a potential target in cancer: Killing many birds with one stone. Hematology/Oncology and Stem Cell Therapy 7:1, pages 1-17.
Crossref
Crossref
Carlos M. Galmarini, Olivier Tredan & Felipe C. Galmarini. (2013) Concomitant resistance and early-breast cancer: should we change treatment strategies?. Cancer and Metastasis Reviews 33:1, pages 271-283.
Crossref
Crossref
Hatem Soliman, Farah Khalil & Scott Antonia. (2014) PD-L1 Expression Is Increased in a Subset of Basal Type Breast Cancer Cells. PLoS ONE 9:2, pages e88557.
Crossref
Crossref
Yong-Hua Wang, Yan-Wei Cao, Xue-Cheng Yang, Hai-Tao Niu, Li-Jiang Sun, Xin-Sheng Wang & Jing Liu. (2014) Effect of TLR4 and B7-H1 on Immune Escape of Urothelial Bladder Cancer and its Clinical Significance. Asian Pacific Journal of Cancer Prevention 15:3, pages 1321-1326.
Crossref
Crossref
Xinguo Jiang & David J. Shapiro. (2014) The immune system and inflammation in breast cancer. Molecular and Cellular Endocrinology 382:1, pages 673-682.
Crossref
Crossref
CUN ZHANG, WEIHUA WANG, XIN QIN, YUJIN XU, TONGLIE HUANG, QIANG HAO, WEINA LI, SHOUZHEN WU & YINGQI ZHANG. (2013) B7-H1 protein vaccine induces protective and therapeutic antitumor responses in SP2/0 myeloma-bearing mice. Oncology Reports 30:5, pages 2442-2448.
Crossref
Crossref
Clare Y. Slaney, Jai Rautela & Belinda S. Parker. (2013) The Emerging Role of Immunosurveillance in Dictating Metastatic Spread in Breast Cancer. Cancer Research 73:19, pages 5852-5857.
Crossref
Crossref
M. Campiglio, R. Bufalino, M. Sasso, E. Ferri, P. Casalini, V. Adamo, A. Fabi, R. Aiello, F. Riccardi, E. Valle, V. Scotti, G. Tabaro, D. Giuffrida, E. Tarenzi, A. Bologna, G. Mustacchi, F. Bianchi, A. Balsari, S. Ménard & E. Tagliabue. (2013) Effect of adjuvant trastuzumab treatment in conventional clinical setting: an observational retrospective multicenter Italian study. Breast Cancer Research and Treatment 141:1, pages 101-110.
Crossref
Crossref
Lisa M. CoussensLaurence ZitvogelA. Karolina Palucka. (2013) Neutralizing Tumor-Promoting Chronic Inflammation: A Magic Bullet?. Science 339:6117, pages 286-291.
Crossref
Crossref